Industry News
Pharmaceutical Industry News
Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds
By mid-2024, the weight-loss drugs were prescribed for almost 2 percent of new mothers.
The FDA signed off on Imfinzi as…
The FDA signed off on Imfinzi as the first immunotherapy that can treat certain patients with early-stage stomach cancer both before and after surgery, marking the drug's third perioperative nod.
Nominate up-and-coming…
Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's "Rising Stars" Q&A series.
Sarepta will study its gene…
Sarepta will study its gene therapy Elevidys with the immunosuppressant sirolimus in non-ambulatory patients with Duchenne muscular dystrophy in the hopes of quelling the liver safety issues that led to a label restriction.
A short film that premiered…
A short film that premiered earlier this month follows three people who, after being diagnosed with chronic lymphocytic leukemia, discover a renewed commitment to living their lives to the fullest.
A survey has found that pharma…
A survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of artificial intelligence models, with 65% of respondents saying they don’t trust the technology to create regulatory compliance submissions.
Novartis has received an FDA…
Novartis has received an FDA approval for Itvisma, an intrathecal version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy.
Less than a week after Novartis…
Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is making moves in
The PMCPA has ruled that a…
The PMCPA has ruled that a presentation calling the European Medicines Agency “stupid” brought discredit on the pharma industry.
A few months after SK Life Science…
A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad.
Novo Nordisk has come up short in…
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's
A combination of Merck-partnered…
A combination of Merck-partnered sac-TMT and Keytruda led to a “statistically significant and clinically meaningful” improvement in progression-free survival versus Keytruda alone in a phase 3 trial in first-line PD-L1-positive NSCLC, Kelun said Monday.
Cada vez más adolescentes toman antidepresivos. Podrían alterar su vida sexual por años
Los estudios sobre adultos que toman ISRS muestran que estos medicamentos reducen la libido. ¿Por qué no se analiza lo que esto podría significar para los chicos?
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone.
Eli Lilly’s latest high-profile…
Eli Lilly's latest high-profile crossovers—which include a starry TV partnership and the far-reaching rollout of a new campaign—both tie into the drugmaker’s work to draw more attention to Alzheimer’s disease.
Maryland is becoming the home away…
Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to increase its manufacturing
ACS CAN’s Pam Traxel joins…
ACS CAN’s Pam Traxel joins Health@WPP’s Wendy Lund to unpack what patients need most amid growing complexity in cancer care.
The approval came “months earlier…
The approval came "months earlier than anticipated," Pfizer's Chief Oncology Officer, Jeff Legos, Ph.D., said in a statement.
The FDA has opened an…
The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug.
Cosette had been attempting to…
Cosette had been attempting to invalidate its $430 million buyout of Australia's Mayne Pharma since May and has now seen its wish granted based on a national security concern from the Australian government.